Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Early results from a 3rd gen EGFR-TKI in advanced NSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.18
Views: 1671
Rating:

Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, the Republic of Korea

Dr Cho speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase I/II trial of lazertinib, a highly selective and irreversible investigational 3rd-generation EGFR-TKI.

He describes the activity of lazertinib in targeting EGFR mutations and T790M mutation, while sparing wild type, and that the drug penetrates the blood-brain barrier (BBB) which has led to marked response in brain metastases.

Across all evaluable patients, the overall response rate was 64%, and Dr Cho outlines further trial expansion and evaluation which will confirm any survival benefit.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

NCRI 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation